Ruthenium Complexes as Promising Candidates against Lung Cancer

Molecules

Hongdong Shi¹  Qianling Zhang¹  Jitian Zhang²  Qi Sun³  Yingsi Li³  Yi Wang⁴ 

[1] College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, China;Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Haiyuan 1st Road, Futian District, Shenzhen 518053, China;International Cancer Center, Guangdong Key Laboratory for Genome Stability & Disease Prevention, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen 518060, China;Key Laboratory for Advanced Materials of MOE, School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai 200237, China;

关键词: Ruthenium complexes;    lung cancer;   

DOI  :  10.3390/molecules26154389

来源: DOAJ

【 摘 要 】

Lung cancer is one of the most common malignancies with the highest mortality rate and the second-highest incidence rate after breast cancer, posing a serious threat to human health. The accidental discovery of the antitumor properties of cisplatin in the early 1960s aroused a growing interest in metal-based compounds for cancer treatment. However, the clinical application of cisplatin is limited by serious side effects and drug resistance. Therefore, other transition metal complexes have been developed for the treatment of different malignant cancers. Among them, Ru(II/III)-based complexes have emerged as promising anticancer drug candidates due to their potential anticancer properties and selective cytotoxic activity. In this review, we summarized the latest developments of Ru(II/III) complexes against lung cancer, focusing mainly on the mechanisms of their biological activities, including induction of apoptosis, necroptosis, autophagy, cell cycle arrest, inhibition of cell proliferation, and invasion and metastasis of lung cancer cells.

【 授权许可】

Unknown